Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses

The main composite renal endpoint from VERTIS CV didn’t show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor. Medscape Medical News
Read More

Leave a Reply

%d bloggers like this: